Delving into the Latest Updates on CGP-28237 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

CGP 28237, ZK 34228, ZK-34228

Target

COX

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Rheumatic Diseases

Originator Organization

Novartis Pharma AG

Active Organization-

Inactive Organization

Bayer AGNovartis Pharma AG

Drug Highest PhaseDiscontinuedPhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC16H15NO4S

InChIKeyBVWQEBWCUCGHHZ-UHFFFAOYSA-N

CAS Registry75360-85-9

Indomethacin inhibited the formation of PGE₂, 6-keto-PGF_1α, and TXB_a in gastric acid ileal mucosa.By contrast, CGP 28237 depressed the formation of 6-keto-PGF_1α in the stomach at 100 mg/kg, but not after 4 doses of 100 mg/kg.Neither drug affected the formation of LTC₄.The gastrointestinal tolerability of CGP 28237 may relate to its lack of effect on cyclooxygenase metabolic products.

01 Jan 1988·Die Pharmazie

6-Sulfanilamidoindazole arthritis in rats: influence of the new anti-inflammatory agent CGP 28237 and of the immunomodulating compound HWA 486 on degree of arthritis and on acute phase reaction.

Article

Author: Hirschelmann, R ; Schade, R

01 Aug 1987·Agents and actions

The anti-inflammatory pharmacologic profile of CGP 28237 (5-methylsulfonylamino-6-phenoxy-1-indanone)

Article

Author: M. Grüninger ; B. Jagher ; Ch. Rordorf-Adam ; I. Böttcher

CGP 28237 is a novel potent inflammation inhibitor, as shown in animal models of inflammation.The drug has excellent gastrointestinal tolerability.The influence on several disease parameters in the MRL/1 pr/1 pr mice, which spontaneously develop massive lymphoproliferation and an autoimmune connective tissue disease that shares immunol. and histopathol. similarities with systemic lupus erythematosus and rheumatoid arthritis, as well as its potency in suppressing in vivo interleukin 1-induced acute phase response indicates the therapeutic potential of the drug in autoimmune disease.

100 Deals associated with CGP-28237

Login to view more data